New insider activity at Relmada Therapeutics ( (RLMD) ) has taken place on December 16, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
In recent transactions, CEO Sergio Traversa acquired 27,500 shares of Relmada Therapeutics stock, amounting to a purchase worth $113,300. Additionally, CFO Maged Shenouda purchased 11,665 shares, with the transaction valued at $48,059.
Recent Updates on RLMD stock
In the last 24 hours, Relmada Therapeutics has seen significant developments that have influenced its stock performance. The company’s stock was upgraded to ‘Outperform’ by Mizuho, with a new price target set at $10, up from $1. This upgrade is primarily driven by the promising potential of NDV-01, a treatment for non-muscle invasive bladder cancer, which has shown a 92% complete response rate in recent data. Mizuho’s confidence is bolstered by the drug’s de-risked and differentiated profile, along with an estimated $2 billion in peak sales. Additionally, Relmada’s strategic pipeline developments and recent acquisitions, despite the high-risk nature typical of biotech firms, contribute to the positive outlook. However, the company’s financial performance remains challenged by zero revenue and significant cash burn, though it is supported by strong cash reserves.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
YTD Price Performance: 868.89%
Average Trading Volume: 1,039,513
Technical Sentiment Signal: Hold
Current Market Cap: $297.7M